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Abstract
Introduction: Given that breast cancers in germline BRCA1 carriers are predominantly estrogen-negative and triple-
negative, it has been suggested that women diagnosed with triple-negative breast cancer (TNBC) younger than
50 years should be offered BRCA1 testing, regardless of family cancer characteristics. However, the predictive value
of triple-negative breast cancer, when taken in the context of personal and family cancer characteristics, is
unknown. The aim of this study was to determine whether TNBC is a predictor of germline BRCA1 mutations, in
the context of multiple predictive factors.
Methods: Germline mutations in BRCA1 and BRCA2 were analyzed by Sanger sequencing and multiple ligation-
dependent probe amplification (MLPA) analysis in 431 women from the Malaysian Breast Cancer Genetic Study,
including 110 women with TNBC. Logistic regression was used to identify and to estimate the predictive strength
of major determinants. Estrogen receptor (ER) and phosphatase and tensin homologue (PTEN) status were assessed
and included in a modified Manchester scoring method.
Results: Our study in an Asian series of TNBC patients demonstrated that 27 (24.5%) of 110 patients have germline
mutations in BRCA1 (23 of 110) and BRCA2 (four of 110). We found that among women diagnosed with breast
cancer aged 36 to 50 years but with no family history of breast or ovarian cancer, the prevalence of BRCA1 and
BRCA2 mutations was similar in TNBC (8.5%) and non-TNBC patients (6.7%). By contrast, in women diagnosed with
breast cancer, younger than 35 years, with no family history of these cancers, and in women with a family history
of breast cancer, the prevalence of mutations was higher in TNBC compared with non-TNBC (28.0% and 9.9%; P =
0.045; and 42.1% and 14.2%; P < 0.0001, respectively]. Finally, we found that incorporation of estrogen-receptor and
TNBC status improves the sensitivity of the Manchester Scoring method (42.9% to 64.3%), and furthermore,
incorporation of PTEN status further improves sensitivity (42.9% to 85.7%).
Conclusions: We found that TNBC is an important criterion for highlighting women who may benefit from
genetic testing, but that this may be most useful for women with early-onset breast cancer (35 years or younger)
or with a family history of cancers. Furthermore, addition of TNBC and PTEN status improves the sensitivity of the
Manchester scoring method and may be particularly important in the Asian context, where risk-assessment models
underestimate the number of mutation carriers.
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Introduction
Discovery of the breast cancer-predisposition genes
BRCA1 and BRCA2 has enabled us to identify carriers
accurately, to target the reduction of risk of breast and
ovarian cancers in carriers, and to develop a new genera-
tion of targeted therapies (PARP inhibitors) [1]. However,
given that deleterious mutations in these genes account
for only 1% to 4% of all breast cancer cases across differ-
ent populations [2] and that genetic testing and genetic
counseling have hitherto been relatively expensive,
genetic testing for BRCA1 and BRCA2 has typically been
offered only in clinical genetics settings to women who
have early-onset breast cancer, and/or to individuals with
significant family history of breast and ovarian, or other
BRCA-related cancers.
Recently, it was suggested that screening women with
early-onset triple-negative breast cancer (TNBC) may be a
cost-effective method with which to identify BRCA1 muta-
tion carriers in Caucasian women [3-5]. This is because, in
the majority of BRCA1 carriers, breast tumors have distinc-
tive morphologic features and immunohistochemical phe-
notypes characteristic of basal-like breast cancers,
including negative expression of the estrogen receptor,
high expression of basal markers, such as basal cytokeratins
CK5/6 and CK14, and loss of tumor-suppressor PTEN
[6-8]. Moreover, molecular gene-expression profiling of
BRCA1 tumors showed that the tumors have significant
similarities with the basal-like subtype of breast cancer [9].
Up to 50% of women diagnosed with breast cancer,
younger than 50 years, and women who have a family can-
cer history may have mutations in BRCA1 or BRCA2 [10].
However, it is notable that although more than 10%
women in whom an isolated TNBC develops at younger
than 40 years old may have a mutation in BRCA1 [3-5],
insufficient evidence exists for those aged 41 to 50 years,
with no family history of breast or ovarian cancer [11].
The purpose of this study was to determine whether
TNBC is an independent criterion for stratifying women
with an increased risk of having a BRCA1 mutation and to
determine whether the addition of immunohistologic fea-
tures of basal-like breast cancers helps to define a subset
of women who are likely to have germline mutations in
BRCA1.
Materials and methods
MyBrCa Breast cancer cohort
The recruitment of breast cancer patients into the Malay-
sian Breast Cancer Genetic Study (MyBrCa) started in Jan-
uary 2003 at the University Malaya Medical Centre in
Kuala Lumpur. All were histopathology-proven breast car-
cinomas. Histomorphologic and biomarker parameters
were retrieved from the histopathology reports. Blood,
demographic, and family-history data were collected from
breast cancer patients who consented to participate in this
study. This study was approved by the ethics committee of
University Malaya Medical Centre.
Analysis of BRCA1 and BRCA2
From January 2003 to February 2012, 1,454 breast cancer
patients were recruited into the MyBrCa study. Germline
DNA samples were screened for BRCA1 and BRCA2
mutations for all women with (a) early-onset breast can-
cer (≤35 years of age) (35 with and 96 without family his-
tory of breast and ovarian cancer); (b) family history of
breast or ovarian cancer in first- and second-degree rela-
tives (193 women); or (c) isolated triple-negative breast
cancer diagnosed at between 36 and 50 years old in the
absence of family history (47 women). In addition, of the
432 women who were diagnosed aged 36 to 50 years with
non-TNBC, 60 women with the highest risk were ana-
lyzed (bilateral breast cancer, breast and ovarian cancer
in the index patient, family history of breast and ovarian
cancer in third-degree or isolated breast cancer (≤45
years of age)). Mutation detection for germline BRCA1
and BRCA2 mutations was conducted by using direct
DNA sequencing and multiple ligation-dependent probe
amplification (MLPA), as previously described [12,13].
Pathologic analysis
For this cohort, patients were classified as having TNBC
when we found <10% ER-, <10% PR-, and 0 or ≤2+ HER2
staining with immunohistochemistry. HER2 was not routi-
nely tested for in all patients prior to 2006, and therefore,
in 259 patients, HER2 status was unavailable. Of the 110
women for whom germline BRCA1 and BRCA2 mutations
were analyzed, adequate archived paraffinized invasive
tumor tissue for evaluation was available from 32 index
patients and two relatives. All cases were tested with
immunohistochemistry for cytokeratin 5/6 (D5/16B4;
Dako Ltd.), cytokeratin 14 (LL02; Novocastra Labs), and
PTEN (6H2.1; Dako). Cytokeratin 5/6 or cytokeratin 14
was defined as positive if >10% of invasive tumor cells
showed cytoplasmic staining [14], and PTEN was defined
as negative if PTEN staining was undetectable in tumor
cells in contrast to adjacent normal stromal cells [6-8].
Description of other pathologic features was conducted as
previously described [14].
Statistical methods
Unconditional multiple linear logistic regression was used
to model the probability that the proband was a mutation
carrier as a function of her personal and family history
and age at diagnosis, as described in [15].
Manchester score analysis
Manchester score was calculated as previously described
[16]. In brief, this system assigns scores depending on the
type of cancer and age at diagnosis and developed such
Phuah et al. Breast Cancer Research 2012, 14:R142
http://breast-cancer-research.com/content/14/6/R142
Page 2 of 9
that a score of 15 was equivalent to a 10% chance of
identifying a BRCA1 or BRCA2 mutation. The modified
method [17-19] includes upward adjustments for TNBC
(+4), estrogen-negative (+1), and high-grade invasive can-
cers (+2), and downward adjustments for human epider-
mal growth factor receptor 2 (HER2)-positive (-4) or
estrogen-receptor positive (-1), lobular (-2), and low-
grade noninvasive cancers (-2). For individuals in whom
tumor tissue was available for PTEN staining, upward
(+1) and downward (-1) adjustments were made for the
absence or presence of PTEN staining, respectively.
Results
Prevalence of BRCA1 and BRCA2 germline mutations is
higher among subsets of women with TNBC compared
with non-TNBC
Of the 1,454 breast cancer patients in the MyBrCa Study,
177 (12.2%) had TNBC based on pathology reports. Of
these 177 women, 50 older than 50 years developed breast
cancer and did not have any family history of breast or
ovarian cancer in first- or second-degree relatives and
were therefore excluded from the study. Of the remaining
127 women, 63 had already been analyzed because of
family history of either breast and/or ovarian cancer (38
individuals, 13 BRCA1 and three BRCA2 carriers, muta-
tion prevalence, 42.1%) or early-onset breast cancer (25
individuals, seven BRCA1 and no BRCA2 carriers; muta-
tion prevalence, 28.0%]. Of the remaining 64 women diag-
nosed at ages 36 through 50 years, but with no family
history of breast or ovarian cancer, 47 women were
screened for germline mutations in BRCA1 and BRCA2
genes, and three BRCA1 and one BRCA2 carriers were
identified (mutation prevalence, 8.5%). Overall, of the 110
women who developed TNBC and were analyzed (63 with
and 47 without family history of breast and ovarian can-
cers), 23 BRCA1 and 4 BRCA2 carriers were identified,
giving a mutation prevalence of 24.5% (Table 1).
In total, 321 women with non-TNBC were analyzed.
This included all women with a family history of breast
and/or ovarian cancer (190 individuals, 10 BRCA1 and
17 BRCA2 carriers, mutation prevalence 14.2%) and
women diagnosed at 35 years or younger with no family
history of breast and ovarian cancer (71 individuals,
three BRCA1 and four BRCA2 carriers; mutation preva-
lence, 9.9% (Table 2)). In addition, of the 432 women
who were diagnosed aged 36 through 50 years with
non-TNBC, 60 women with the highest risk were ana-
lyzed (bilateral breast cancer, breast and ovarian cancer
in the index patient, family history of breast and ovarian
cancer in third degree or isolated breast cancer (aged 45
years or younger)). Of these 60 women, one BRCA1 and
three BRCA2 carriers were found [mutation prevalence,
6.7%]. Overall, of the 321 non-TNBC women analyzed,
14 BRCA1 and 24 BRCA2 carriers were identified, giving
a mutation prevalence of 11.8%.
We compared the prevalence of BRCA1 and BRCA2
mutations in the women who developed TNBC and
non-TNBC. Of the women with low familial risk of
breast and ovarian cancer (diagnosed 36 to 50 with no
family history of breast or ovarian cancer], 6.4% and
1.7% of women with TNBC and non-TNBC were found
to be BRCA1 carriers, respectively, whereas 2.1% and
5.0% were BRCA2 carriers. Overall, 8.5% of women with
TNBC and 6.7% of women with non-TNBC were found
to have germline BRCA1 or BRCA2 mutations. This
suggests that, regardless of the TNBC status, in the
absence of family history of breast or ovarian cancer in
this age group, a low (<10%) probability exists of having
a BRCA1 or BRCA2 mutation.
By contrast, in two other groups of women, a signifi-
cantly higher prevalence of BRCA1 mutations was found
in women who developed TNBC versus non-TNBC.
First, of the women in whom breast cancer developed at
35 years or younger, 28.0% of women with TNBC were
BRCA1 or BRCA2 carriers compared with only 9.9%
among those who developed non-TNBC (P = 0.045).
Notably, all 28.0% of women diagnosed with TNBC at
younger than 35 years were BRCA1 carriers, compared
with 4.2% BRCA1 and 5.6% BRCA2 among women diag-
nosed with non-TNBC.
Second, of women who had a family history of breast
and/or ovarian cancer, 42.1% of women with TNBC were
BRCA1 or BRCA2 carriers compared with 14.2% of those
with non-TNBC (P = < 0.0001). This is largely because of
a difference in prevalence of BRCA1 mutations in TNBC
compared with non-TNBC (34.2% compared with 5.3%;
P = < 0.0001), as no significant difference occurred in the
prevalence of BRCA2 in both subsets of women (7.9%
compared with 8.9%; P = 1.00). Notably, no significant dif-
ference was noted in average age at onset of breast cancer
in the index patient, or the mean number of first-degree
relatives of women in whom TNBC developed compared
with the non-TNBC (seven relatives), but the mean num-
ber of affected relatives in the non-TNBC group was
higher than that in the TNBC group (0.8 compared with
0.6; P = 0.003). This suggests that the higher prevalence of
BRCA1 mutations in the women in whom TNBC devel-
oped compared with women in whom non-TNBC devel-
oped is not due to a difference in the age at onset or
strength of family history. Taken together, the results sug-
gest that early onset and familial breast cancer patients in
whom TNBC develops are more likely to have mutations
in the BRCA1 genes compared with those in whom non-
TNBC develops (24.5% versus 11.8%; P = 0.001).
In addition, in this cohort, a marked difference
appears in prevalence of BRCA1 and BRCA2 in the
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TNBC and non-TNBC patients. TNBC patients are
more likely to have BRCA1 than BRCA2 mutations
(20.9% and 4.4%; p < 0.0001), whereas no statistically
significant difference is present in BRCA1 and BRCA2
mutations in non-TNBC patients (3.6% and 7.5%,
respectively; P = 0.158).
Logistic regression analyses
Given the possible confounding between the age of diag-
nosis, subtype of breast cancer, and family history of can-
cer, it has been demonstrated that the predictive effects of
factors should be based on an analysis that takes into
account all factors simultaneously [15]. By using binary
logistic regression analysis, we found that age at diagnosis
of breast cancer, having any family history of breast or
ovarian cancer, and having triple-negative breast cancer
were associated with a 2.6-fold (confidence interval (CI),
1.4 to 4.8; P < 0.003), 3.5-fold (CI, 1.9 to 6.8; P < 0.0001),
and 3.5-fold (CI, 1.91 to 6.3; P < 0.0001) increase in risk of
being a BRCA1 or BRCA2 carrier, respectively. No
evidence of interaction effects between these factors was
seen. With multiple linear logistic regression analysis, the
strongest predictors of mutation status were breast cancer
in the proband if age at diagnosis was younger than 35
years (P = 0.043), with bilateral breast cancer (P = 0.025),
with triple-negative breast cancer (P < 0.0001), with breast
cancer in a first-degree relative if age at diagnosis was
younger than 60 years (P < 0.01), or ovarian cancer was
present in a first- or second-degree relative (P < 0.025)
(Table 3).
The probability that a proband with a given set of per-
sonal and family characteristics is a mutation carrier can
be estimated from the model fit shown in Table 4. Start-
ing with the log odds score of θ (the baseline coeffi-
cient), add the respective regression coefficient (b) for
each personal characteristic and the respective regres-
sion for each family characteristic multiplied by the
number of affected relatives. In this model, an overall
score of -1.5 is equivalent to a 15% probability of being
a BRCA1 or BRCA2 carrier. Notably, the overall scores
Table 1 Characteristics of women tested for germline BRCA1 and BRCA2 mutations
Characteristics Total BRCA1 BRCA2 BRCA1 and -2
n (%) n (%) n (%) n (%)
Female breast, age at index diagnosis, years
≤30 50 11.6 8 16.0 2 4.0 10 20.0
31-40 164 38.1 17 10.4 13 7.9 30 18.3
41-50 144 33.4 8 5.6 8 5.6 16 11.1
>50 73 16.9 4 5.5 5 6.8 9 12.3
Breast or ovarian cancers in family (first and second degree only)
Female breast 217 50.3 21 9.7 20 9.2 41 18.9
Female ovary 19 4.4 6 31.6 3 15.8 9 47.4
Manchester score
≤10 205 47.6 5 2.4 6 2.9 11 5.4
11-17 146 33.9 16 11.0 10 6.8 26 17.8
≥18 80 18.6 16 20.0 12 15.0 28 35.0
Ancestry
Malay 115 26.7 8 7.0 9 7.8 17 14.8
Chinese 248 57.5 15 6.0 16 6.5 31 12.5
Indian 59 13.7 12 20.3 3 5.1 15 25.4
Others 9 2.1 2 22.2 0 0.0 2 22.2
Referral characteristic
Early onset ≤35 years, regardless of family history 131 30.4 17 13.0 8 6.1 25 19.1
Two cases of breast cancer, one <50 years 126 29.2 10 7.9 11 8.7 21 16.7
Three cases of breast or ovarian cancer 76 17.6 13 17.1 12 15.8 25 32.9
One case of bilateral breast cancer <50 years, in index or first- and
second-degree relative
39 9.0 10 25.6 3 7.7 13 33.3
One case of breast and ovarian cancer in same individual in index or first-
and second-degree relative
8 1.9 3 37.5 1 12.5 4 50.0
Triple-negative breast cancer, ≤50 years 98 22.7 20 20.4 3 3.1 23 23.5
In total, 431 breast cancer patients were analyzed for germline mutations in BRCA1 and BRCA2 by DNA sequencing and multiple ligation-dependent probe
amplification (MLPA) analysis. Table 1 shows the distribution of women according to their age at diagnosis, family history of breast and ovarian cancer in first-
and second-degree relatives, Manchester score and self-declared ethnicity, and the prevalence of BRCA1 and BRCA2 mutations in each category.
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for women with isolated TNBC who were diagnosed
aged ≤35 years old, 36 to 39 years old, or 40 to 49 years
old, are -1.1, -1.6, and -2.1, respectively, which correlates
with a 29%, 14%, and 9% probability of being a BRCA1
or BRCA2 carrier. The overall scores for women with
isolated non-TNBC who were diagnosed at younger
than 35 years, 36 to 39 years old, and 40 to 49 years
old, are -2.4, -2.9, and -3.4, respectively, which correlates
with a 9%, 4%, and 4% probability of being a BRCA1 or
BRCA2 carrier. These results show that women with
isolated TNBC have a higher probability of being car-
riers compared with women with isolated non-TNBC
and that, of the women with isolated breast cancers,
only women with isolated TNBC diagnosed at younger
than 40 years have a greater than 10% probability of
having germline mutations in BRCA1 or BRCA2.
Table 2 Characteristics of women tested for germline BRCA1 and BRCA2 mutations
Characteristics Triple negative Not triple negative P value
n = 110 n = 321
n BRCA1 BRCA2 Total
(%)
n BRCA1 BRCA2 Total
(%)
With family history
Early onset, ≤35 years old 6 4 0 4 (66.7) 29 3 4 7 (24.1) 0.063a
>35 years old 32 9 3 12 (37.5) 161 7 13 20 (12.4) 0.0005b
Overall 38 13 3 16 (42.1) 190 10 17 27 (14.2) <0.0001b
Without family history
Early onset, ≤35 years old 25 7 0 7 (28.0) 71 3 4 7 (9.9) 0.045a
36 to 50 years old 47 3 1 4 (8.5) 60 1 3 4 (6.7) 1.000a
Overall 72 10 1 11 (15.3) 131 4 7 11 (8.4) 0.131b
All, regardless of family history or age 110 23 4 27 (24.5) 321 14 24 38 (11.8) 0.001b
Mean age at diagnosis (years) 40.6 42.0 0.172
Mean number of first-degree relatives 7.2 7.1 0.827
Mean number of affected (breast or ovarian) relatives, first or second
degree
0.6 0.8 0.003
Prevalence of BRCA1 mutations 20.9% 4.4% <0.0001b
Prevalence of BRCA2 mutations 3.6% 7.5% 0.158b
aFisher Exact test. bc2 test. The prevalence of germline mutations in BRCA1 and BRCA2 (combined) in the 431 breast cancer patients analyzed, in whom 110
developed triple-negative breast cancer, and 321 did not. Family history includes presence of breast or ovarian cancer in first- and second-degree relatives,
bilateral breast cancer in the index patient or relative, or breast and ovarian cancer in the same individual in the index patient or relative. P values were
calculated by using Fisher Exact or c2 test, and mean values were calculated by using independent t test.
Table 3 Logistic regression coefficients (ß), standard errors, and nominal significance levels of potentially predictive
factors for BRCA1 or BRCA2 carriers
Characteristic b Standard error P
Baseline -5.169 1.388 0.000
Proband breast cancer diagnosis ≤35 years 2.791 1.379 0.043
Proband breast cancer diagnosis 36-39 years 2.248 1.365 0.100
Proband breast cancer diagnosis 40-49 years 1.763 1.355 0.193
Proband breast cancer diagnosis 50-59 years 1.065 1.354 0.431
Proband bilateral breast cancer at any age 1.036 0.462 0.025
Proband ovarian cancer at any age 0.238 1.469 0.871
Proband triple-negative breast cancer at any age 1.323 0.331 0.000
For each relative with cancer:
First degree, breast cancer diagnosis ≤39 years 0.950 0.369 0.010
First degree, breast cancer diagnosis 40-49 years 1.450 0.386 0.000
First degree, breast cancer diagnosis 50-59 years 1.445 0.450 0.001
First degree, breast cancer diagnosis 60+ years 0.207 0.646 0.749
First degree, ovarian cancer at any age 2.556 0.769 0.001
Second degree, breast cancer diagnosis at any age 0.359 0.272 0.187
Second degree, ovarian cancer diagnosis at any age 1.861 0.832 0.025
The multiple linear logistic regression analysis of the probability of breast cancer patients having a germline mutation in the BRCA1 or BRCA2 gene on the basis
of age at diagnosis and family history of breast or ovarian cancers.
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Pathologic features of BRCA1 and non-BRCA1 triple-
negative breast cancer
We analyzed the pathology reports of BRCA1 carriers and
compared them with those in BRCA2 and non-BRCA car-
riers. Of the 31 BRCA1 index carriers and affected rela-
tives where pathology reports were available, 26 (83.9%)
developed TNBC. By contrast, of the 270 BRCA2 carriers
and non-BRCA carriers, 88 (32.6%) developed TNBC.
Of the 110 TNBC patients included in this study and for
whom germline status of BRCA1 and BRCA2 has been
characterized (see earlier), 34 had adequate invasive tumor
tissue for evaluation. Slides were cut and immunostained
for several markers that have been reported to be useful in
defining the basal-like phenotype, including basal cytoker-
atins CK5/6, CK14, and PTEN. Although some higher
grade were present, higher basal cytokeratin, loss of
PTEN, high grade of pleomorphism, presence of pushing
margins, solid sheets, necrosis, and mitosis in BRCA1 car-
riers compared with non-BRCA1 carriers, these differences
were not statistically significant (see Additional file 1).
Inclusion of pathologic features in Manchester scores
To determine whether the addition of pathologic features
can define a subset of women who are likely to have
germline mutations in BRCA1 or BRCA2, we calculated
the Manchester score for each individual based on the
original Manchester score [16] and on the updated Man-
chester score where pathology was included [18]. Upward
adjustments in BRCA1 mutation-prediction scores were
made for grade 3 ductal cancers, estrogen receptor (ER),
and triple-negative tumors, and downward adjustments
in the score were made for grade 1 tumors, lobular can-
cer, ductal or lobular carcinoma in situ, noninvasive
breast cancer, and ER/HER2 positivity, as described pre-
viously [18].
Of the 431 women in this study, 86 were excluded
because pathology reports were incomplete. Without
adjustment, 72 of 345 women had a Manchester score
of ≥15, and this included only 12 of the 28 BRCA1
carriers (sensitivity, 42.9%; specificity, 81.1%; PPV,
16.7%). With the adjustment, 82 of the 345 women had
a Manchester score of ≥15, and this included 18 of the
28 BRCA1 carriers (sensitivity, 64.3%; specificity, 79.8%;
PPV, 22.0%) (Table 5). These results show that adjust-
ment in this cohort resulted in 14% increase in the
number of tests (72 to 82) and 21% increase in sensitiv-
ity (43% to 64%).
In addition, given that PTEN loss was associated with
BRCA1 germline mutations [8], we made a further upward
adjustment for PTEN loss (+1 point) for all patients for
whom PTEN status was available. Without adjustment,
five of 26 women had a >10% probability of BRCA1 and
BRCA2 mutations, and this included only three of the
seven BRCA1 carriers (sensitivity, 42.9%; specificity, 89.5%;
PPV, 60.0%). With the adjustment for PTEN loss, 10 of
the 26 women had a Manchester score ≥15, and this
included six of the seven BRCA1 carriers (sensitivity,
85.7%; specificity, 78.9%; PPV, 60.0%; Table 5). Although
PTEN results were available for only a small subset of
patients, these results suggest that upward adjustment for
PTEN may aid the identification of BRCA1 carriers.
Discussion
Our study in an Asian series of triple-negative breast can-
cer patients demonstrated that up to 24.5% (27 of 110)
women have germline mutations in BRCA1 (23 of 110)
and BRCA2 (four of 110), and that the addition of negative
estrogen-receptor status and PTEN loss improves the sen-
sitivity of the Manchester Scoring method in our Asian
cohort.
The results in this study are consistent with that in
other cohorts of triple-negative breast cancer patients,
in whom 11% to 39% have germline mutations in
BRCA1 and BRCA2 [3,6,20-23], and cohorts of estrogen-
receptor-negative breast cancer patients, of whom 24%
to 29% have germline mutations in BRCA1 and BRCA2
[4,6,24,25]. A recent single-institution study showed that
50% of high-risk patients with TNBC had mutations in
BRCA1/2, but notably, 76% of this cohort had a family
history of breast cancer [10]. For all of these series and
for our study, BRCA1 mutations are more common
than BRCA2 mutations.
Cost-effectiveness analyses have suggested that mutation
testing for all TNBC patients younger than 50 years old
may be a cost-effective approach, assuming that 10% to
25% of these patients have BRCA1 or BRCA2 mutations
[5]. However, we find that although TNBC is associated
with an increased prevalence of BRCA1 and BRCA2 muta-
tions among those younger than 35 years old (28.0% in
TNBC versus 9.9% in non-TNBC; P = 0.045], TNBC is not
associated with an increased prevalence of mutations
among those aged 36 to 50 years without a family history
of breast or ovarian cancer (BRCA prevalence of 8.5% and
Table 4 Overall number of carriers for each predicted









≤3.5 25 0 0
-3.0 to -3.5 49 2 4
-2.5 to -3.0 47 2 4
-2.0 to -2.5 144 13 9
-1.5 to -2.0 58 8 14
-1.0 to -1.5 59 17 29
0 to -1.0 33 11 33
0 to 1 16 12 75
The number of carriers for each predicted range of probability calculated
through incorporation of logistic regression coefficients generated in Table 3.
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6.7%, respectively). This may be because BRCA1 is a high-
penetrance gene and is associated with both early-onset
disease and multiple affected family members, and there-
fore, in the absence of these features, a low prevalence of
BRCA1 mutations is found, even in TNBC. Further studies
with larger population-based datasets are needed to deter-
mine the prevalence of BRCA1 and BRCA2 mutations and
the cost-effectiveness of testing women diagnosed with
isolated breast cancer, aged 40 to 49 years old.
We find that the prevalence of BRCA1 mutations is
higher in TNBC compared with non-TNBC in women
in whom early-onset breast cancer develops and in
women with a family history of breast and ovarian can-
cer. This effect is largely due to a difference in preva-
lence of BRCA1 mutations and is consistent with the
observation that the majority of BRCA1 carriers develop
early-onset triple-negative basal-like breast tumors that
have distinctive morphologic and immunohistochemical
characteristics [6-8]. Intriguingly, the significant propor-
tion of TNBC patients who have BRCA1 germline muta-
tions in these two subgroups of patients (28.0% and
34.2%) suggests that mutation in BRCA1 is a key driver
of the development of TNBC. This could be due to the
roles of BRCA1 in determining cell fate of luminal pro-
genitor cells [26], its effect on transcriptional regulation
of ER-gene expression [27], its effect on regulation of
mi155 [27], or a combination of these.
Taken together, we suggest that TNBC status may be
helpful in stratifying women with a moderate risk of hav-
ing BRCA1 mutations (for example, a weak family history
or isolated case of early-onset breast cancer), but may
have limited utility in the absence of such features (for
example, women with a single case of TNBC aged 40 to
50 years old).
Finally, we find that addition of negative estrogen
receptor and TNBC status improves the sensitivity and
specificity of the Manchester Scoring method in our
cohort and that addition of PTEN loss further improves
the sensitivity of the method. PTEN loss is highly asso-
ciated with BRCA1 breast cancers (28 (82.4%) of 34 of
tumor samples from BRCA1 carriers showed the loss of
PTEN by immunohistochemistry) and can result from
gene rearrangements involving DNA double-strand
breaks, intragenic inversions on insertions, homozygous
deletions, and focalized CNIs [8]. However, given that the
data on PTEN loss were available on only a small subset
of patients, this result requires further validation in a lar-
ger cohort of patients. We believe that methods for strati-
fying the likelihood of carrying a BRCA1 and BRCA2
mutation that is independent of family history are impor-
tant, particularly in the Asian context, because the famil-
ial and social stigma associated with cancer makes
accurate family-history reporting challenging [28].
Conclusions
In previous studies and in our cohort of TNBC, a signif-
icant proportion of women have germline BRCA1 muta-
tions. Our study shows that among women with early-
onset breast cancer (≤35 years old) and with a family
history of breast cancer, a higher prevalence of BRCA1
mutations is present in women with TNBC compared
with women with non-TNBC. However, no difference in
prevalence of BRCA1 and BRCA2 mutations is noted
among women who develop isolated breast cancer aged
36 to 50 (7% to 8% prevalence in both TNBC and non-
TNBC). Our study suggests that the current clinical
recommendations of offering BRCA1 and BRCA2
genetic testing, even to women with isolated TNBC
younger than 60 years, warrants further analysis.
Additional material
Additional file 1: CK, cytokeratin. Characteristics of BRCA1 carriers
Additional File 1 shows the pathologic features of breast cancers in eight
BRCA1 carriers compared with 26 non-BRCA1 carriers.
Abbreviations
BRCA1: breast cancer 1 gene; BRCA2: breast cancer 2 gene; CK: cytokeratin;
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epidermal growth factor receptor 2; MyBrCa: Malaysian Breast Cancer
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progesterone receptor; PTEN: phosphatase and tensin homologue; TNBC:
triple-negative breast cancer.
Table 5 Performance of Manchester Scoring method before and after adjustment with ER status or ER and PTEN
status















345 28 72 12 82 18
Adjustment + estrogen-receptor +
PTEN status
26 7 5 3 10 6
The predicted and observed numbers of BRCA1 and BRCA2 (combined) carriers in women with low (1 to 14) and high Manchester score, either without
adjustment for pathologic features, or with adjustment for ER status and other features [17-19], or further adjustment including +1 for loss of PTEN.
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